Manager 2
Alkeus Pharmaceuticals
Manager 2
Alkeus Pharmaceuticals
Develops ALK-001 therapy for Stargardt
Alkeus Pharmaceuticals, Inc. is a clinical-stage biotech company focused on the development of innovative therapies to treat serious diseases of the eye with high unmet need. Based in Cambridge, Mass., Alkeus was founded in 2010, and since that time has been developing its lead compound, gildeuretinol acetate (ALK-001). Designated as a breakthrough therapy and granted orphan drug status by the U.S. Food and Drug Administration, gildeuretinol is being evaluated in multiple clinical trials for the treatment of Stargardt disease and geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a leading cause of blindness in the U.S.
Position Summary:
The Manager II, Clinical Studies provides strategic and operational leadership for assigned clinical studies from study planning and start-up through execution, database lock, closeout, and archival. The Manager II, Clinical Studies is accountable for the successful operational delivery of assigned studies, ensuring that timelines, budgets, quality standards, and key study objectives are achieved.
Working closely with Clinical Development, Clinical Science, Data Management, Biostatistics, Regulatory Affairs, Drug Safety, Quality Assurance, Clinical Supply, and other functions, the Sr. CSM ensures coordinated and compliant execution of clinical studies in accordance with applicable regulatory requirements, Good Clinical Practice (GCP), company procedures, and study protocols.
Primary Responsibilities:
Clinical Study Leadership and Execution
CRO and Vendor Management
Site Management and Study Oversight
Regulatory Compliance, Quality and Inspection Readiness
Budget and Financial Management
Clinical Operations Excellence
Qualifications:
Other Relevant Information:
Compensation
Alkeus Pharmaceuticals, Inc. is an equal opportunity employer and considers all qualified applicants for employment without regard to any characteristic protected by applicable law. We participate in E-Verify and conduct background checks as a part of our employment process.
Develops ALK-001 therapy for Stargardt
Alkeus Pharmaceuticals develops therapies for genetic eye diseases, with ALK-001 as its lead candidate for Stargardt disease. Stargardt is caused by ABCA4 gene defects, leading to toxic by-products that damage vision. ALK-001 is a modified form of vitamin A that preserves the necessary functions of vitamin A for sight but reduces formation of harmful by-products, addressing a condition with no approved treatments for many patients in the US. The product works by altering vitamin A chemistry to prevent toxic buildup while supporting normal visual processes. The company earns by researching, patenting, and eventually selling its therapies to healthcare providers and patients. Its focus on Stargardt disease positions it in a niche genetic-eye-disease market with potential applicability to other retinal disorders, offering a path to a scalable therapy through drug development and IP protection.
Explore more opportunities at Alkeus Pharmaceuticals